Immunosuppression, BK polyomavirus infections, and BK polyomavirus-specific T cells after pediatric kidney transplantation.

Background: After kidney transplantation, immunosuppressive therapy increases risk of BK polyomavirus-associated nephropathy (BKPyVAN). Outcomes of BKPyV viremia are various and prognostic markers are missing. The impact of different immunosuppressive regimens on BKPyV infections is currently under...

Descripción completa

Detalles Bibliográficos
Publicado en:Pediatric Nephrology Vol. 35; no. 4; pp. 625 - 632
Autores principales: Ahlenstiel-Grunow, Thurid, Pape, Lars
Formato: research tables/charts Journal Article
Publicado: Springer Nature Apr2020
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142063073&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 142063073
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        0931041X
        EF1
      jtl: Pediatric Nephrology
      issn: 0931041X
      maglogo: N
    pubinfo:
      dt: Apr2020
      vid: 35
      iid: 4
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        142063073
        142063073
        142063073
        10.1007/s00467-019-04408-2
        142063073
      ppf: 625
      ppct: 7
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Immunosuppression, BK polyomavirus infections, and BK polyomavirus-specific T cells after pediatric kidney transplantation.
      aug:
        au:
          Ahlenstiel-Grunow, Thurid
          Pape, Lars
        affil: Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany
      sug:
        subj:
          Kidney Transplantation In Infancy and Childhood
          Immunosuppression Adverse Effects
          Polyomavirus Infections Complications
          Kidney Diseases Risk Factors
          Risk Assessment
          Human
          Child
          Retrospective Design
          Viremia
          Lymphocyte Count
          Tacrolimus Therapeutic Use
          Cyclosporine Therapeutic Use
          Protein Kinase Inhibitors Therapeutic Use
          Polyomavirus Infections Risk Factors
          Descriptive Statistics
          Child: 6-12 years
      ab: Background: After kidney transplantation, immunosuppressive therapy increases risk of BK polyomavirus-associated nephropathy (BKPyVAN). Outcomes of BKPyV viremia are various and prognostic markers are missing. The impact of different immunosuppressive regimens on BKPyV infections is currently under discussion. Methods: We analyzed immunosuppressive therapy and BKPyV-specific cellular immunity to distinguish patients at risk of BKPyVAN from those with self-limiting viremia for purposes of risk-stratified BKPyV management. In a retrospective analysis, 46 pediatric kidney recipients with BKPyV viremia were analyzed with regard to duration of BKPyV viremia and immunosuppressive therapy; in addition, in 37/46 patients, BKPyV-specific CD4 and CD8 T cells were measured. Results: Nine patients showed persistent BKPyV viremia and BKPyVAN, and required therapeutic intervention, while 37 patients had asymptomatic, self-limiting viremia. At onset of viremia, 78% of patients with persistent viremia and BKPyVAN were treated with tacrolimus, whereas tacrolimus therapy was significantly less frequent in patients with self-limiting viremia (14%). The majority of patients with transient, self-limiting viremia received cyclosporine A (81%) and/or mTOR inhibitors (81%). Patients with persistent BKPyV viremia and BKPyVAN showed lack of BKPyV-specific CD4 and CD8 T cells (6/6), whereas the majority of patients with self-limiting viremia (27/31) had detectable BKPyV-specific CD4 and/or CD8 T cells ≥ 0.5 cells/μl (p < 0.001). Conclusions: These results indicate that tacrolimus enhances risk of BKPyVAN with need of therapeutic intervention, whereas under cyclosporine A and mTOR inhibitors, the majority of pediatric kidney recipients showed self-limiting viremia. In patients at risk of BKPyV infections, combination of cyclosporine A and mTOR inhibitor may be advantageous.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N